Navigation Links
Anti-epilepsy drug risk on cognitive function for unborn children
Date:7/21/2009

LIVERPOOL, UK 21 July 2009: Interim results of a study being conducted by scientists at the University of Liverpool suggest that children aged three years and younger, who are born to women taking the anti-epileptic drug sodium valproate whilst pregnant, are likely to have an IQ of six to nine points lower than average.

The research, in collaboration with Emory University in the US and the Central Manchester University Hospitals NHS Foundation Trust, tested more than 300 three-year-olds in the UK and US, whose mothers took one of four anti-epilepsy drugs (AEDs) whilst pregnant. The preliminary findings suggest that children exposed to the drug sodium valproate had lower IQ results than children exposed to other AEDs, regardless of the mother's IQ. The results also took dosage, duration of pregnancy and mother's consumption of folic acid whilst pregnant, into account.

Professor of Clinical Neuropsychology at the University, Gus Baker, said "Our research looked at how exposure to sodium valproate and other AEDs in the womb affected children's everyday life in particular their IQ, memory and language abilities from one to six years of age."

Around 5,000 women with epilepsy become pregnant every year in the UK and the majority of these, including those on AEDs, will experience uncomplicated pregnancies and births. Previous research conducted by the team has already shown that children exposed to AEDs such as sodium valproate in the womb are more likely to suffer birth defects characterised by heart malformations, dysmorphic features and minor limb deformities.

Professor Baker added: "The answer is not as simple as to take women off AEDs altogether as the effects of suffering a seizure can also pose a risk for both mother and unborn child. It is vital that the research is now used to educate women with epilepsy before they start to plan for a family. Women need to be aware of the risks so that they can make informed choices w
'/>"/>

Contact: Kate Spark
kate.spark@liv.ac.uk
44-151-794-2247
University of Liverpool
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
2. Lack of sleep among new school-goers leads to behavioral, cognitive problems
3. Low level of neuronal receptor linked to mild cognitive impairment and Alzheimers disease
4. Cognitive Activities Protect Against Alzheimers -- Social and Physical Activities Not Enough
5. Potential new approach to treat cognitive impairments in schizophrenia
6. Cognitive deficits lead to loss of self among cancer patients
7. Research links diet to cognitive decline and dementia
8. First Cognitive Training to Demonstrate Immediate Generalizability Through Standardized Assessments of Memory
9. New research on aging and cognitive training presented at GSAs Annual Meeting
10. Hypertension Linked to Risk of Mild Cognitive Impairment
11. Rhode Island Hospital to study driving ability of cognitively impaired elders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
Breaking Medicine News(10 mins):Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
...isk of developing liver cancer and more than twice...researchers based on findings of a recent study. ...agnosed with 12 different types of cancer to 509 h...pendent of other factors like participants' body m...
...researchers suggest that the risk factors for hear...nearly 2,000 teens studied, about two-thirds had a... as 10 percent had a cluster of risk factors known... heart disease and diabetes. For the purpose of th...
...tic hypotension have problems with sinking blood p.../ Current treatments help increase blood pressure ...r when lying down, increasing the risk for stroke....ic hypotension especially common in those over age...
...ncer death worldwide, accounting for more than 1.3...rd to detect in early and treatable stages, most c...tudies have shown CT scans can identify the diseas...ecent study, researchers used PET scans to confirm...
...benefit from early magnetic resonance imaging, acc...o neuroscientists in Canada MRI technology could d...ients. They say they found that trauma-induced spi...ly certain the procedure will benefit the patient,...
... in soy could be good for the hearts and bones of ...parate studies suggest the natural plant estrogens...the body's own estrogen, therefore making soy espe...tter cholesterol levels compared to monkeys who at...
Other Medicine News:Health News:New Drug Effective for Low Blood Pressure 2
(Date:12/4/2009)EMERYVILLE, Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data present
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB 728 T for HIV AIDS 14909 1Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB 728 T for HIV AIDS 14909 2FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans 6392 1FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans 6392 2Genital Herpes May Never Go Dormant 61659 1Genital Herpes May Never Go Dormant 61659 2Genital Herpes May Never Go Dormant 61659 3
...xpansion of Company,s Phase 3 Study for Wet AMD af...ata, FREMONT, Calif., April 17 NeoVista, Inc. an...ration (FDA) has granted the,company,s request to ...votal Phase 3 trial from 10 to 30 in the United St...ndary to AMD Treated with BEta RadiatioN,Epiretina...
...il 17 Innocoll, Inc., a privately-held,biopharmac...e planned phase,2 clinical trials sponsored by its...d, to investigate CollaRx(R) GENTAMICIN TOPICAL fo...c foot ulcers, has commenced,dosing. CollaRx GENTA...ble,Gentamicin-Collagen Sponge formulated and manu...
Other Medicine Technology:FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4
...s for performing erythrocyte sedimentation rate (E...on of the Ves-matic System DIESSE brings to the cl...ting system which addresses and resolves every tec...ESR techique.,By means of a fully automated analyz...
...s for performing erythrocyte sedimentation rate (E...on of the Ves-matic System DIESSE brings to the cl...ting system which addresses and resolves every tec...ESR techique.,By means of a fully automated analyz...
...ntation rate analysers, which are especially user-...well-established advantages of the existing analys...ch guarantee time-saving standardised analysis of ...ness is an essential aspect of daily recurrent rou...
Mix-Rate
Medicine Products: